Literature DB >> 32220282

Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies.

David M Patrick1, Hind Sbihi2, Darlene L Y Dai3, Abdullah Al Mamun4, Drona Rasali5, Caren Rose4, Fawziah Marra6, Rozlyn C T Boutin7, Charisse Petersen7, Leah T Stiemsma8, Geoffrey L Winsor9, Fiona S L Brinkman9, Anita L Kozyrskyj10, Meghan B Azad11, Allan B Becker11, Piush J Mandhane10, Theo J Moraes12, Malcolm R Sears13, Padmaja Subbarao12, B Brett Finlay7, Stuart E Turvey14.   

Abstract

BACKGROUND: Childhood asthma incidence is decreasing in some parts of Europe and North America. Antibiotic use in infancy has been associated with increased asthma risk. In the present study, we tested the hypothesis that decreases in asthma incidence are linked to reduced antibiotic prescribing and mediated by changes in the gut bacterial community.
METHODS: This study comprised population-based and prospective cohort analyses. At the population level, we used administrative data from British Columbia, Canada (population 4·7 million), on annual rates of antibiotic prescriptions and asthma diagnoses, to assess the association between antibiotic prescribing (at age <1 year) and asthma incidence (at age 1-4 years). At the individual level, 2644 children from the Canadian Healthy Infant Longitudinal Development (CHILD) prospective birth cohort were examined for the association of systemic antibiotic use (at age <1 year) with the diagnosis of asthma (at age 5 years). In the same cohort, we did a mechanistic investigation of 917 children with available 16S rRNA gene sequencing data from faecal samples (at age ≤1 year), to assess how composition of the gut microbiota relates to antibiotic exposure and asthma incidence.
FINDINGS: At the population level between 2000 and 2014, asthma incidence in children (aged 1-4 years) showed an absolute decrease of 7·1 new diagnoses per 1000 children, from 27·3 (26·8-28·3) per 1000 children to 20·2 (19·5-20·8) per 1000 children (a relative decrease of 26·0%). Reduction in incidence over the study period was associated with decreasing antibiotic use in infancy (age <1 year), from 1253·8 prescriptions (95% CI 1219·3-1288·9) per 1000 infants to 489·1 (467·6-511·2) per 1000 infants (Spearman's r=0·81; p<0·0001). Asthma incidence increased by 24% with each 10% increase in antibiotic prescribing (adjusted incidence rate ratio 1·24 [95% CI 1·20-1·28]; p<0·0001). In the CHILD cohort, after excluding children who received antibiotics for respiratory symptoms, asthma diagnosis in childhood was associated with infant antibiotic use (adjusted odds ratio [aOR] 2·15 [95% CI 1·37-3·39]; p=0·0009), with a significant dose-response; 114 (5·2%) of 2182 children unexposed to antibiotics had asthma by age 5 years, compared with 23 (8·1%) of 284 exposed to one course, five (10·2%) of 49 exposed to two courses, and six (17·6%) of 34 exposed to three or more courses (aOR 1·44 [1·16-1·79]; p=0·0008). Increasing α-diversity of the gut microbiota, defined as an IQR increase (25th to 75th percentile) in the Chao1 index, at age 1 year was associated with a 32% reduced risk of asthma at age 5 years (aOR for IQR increase 0·68 [0·46-0·99]; p=0·046). In a structural equation model, we found the gut microbiota at age 1 year, characterised by α-diversity, β-diversity, and amplicon sequence variants modified by antibiotic exposure, to be a significant mediator between outpatient antibiotic exposure in the first year of life and asthma diagnosis at age 5 years (β=0·08; p=0·027).
INTERPRETATION: Our findings suggest that the reduction in the incidence of paediatric asthma observed in recent years might be an unexpected benefit of prudent antibiotic use during infancy, acting via preservation of the gut microbial community. FUNDING: British Columbia Ministry of Health, Pharmaceutical Services Branch; Canadian Institutes of Health Research; Allergy, Genes and Environment (AllerGen) Network of Centres of Excellence; Genome Canada; and Genome British Columbia.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32220282     DOI: 10.1016/S2213-2600(20)30052-7

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  34 in total

1.  Associations of early-life factors and indoor environmental exposure with asthma among children: a case-control study in Chongqing, China.

Authors:  Yun-Tian Deng; Xue-Mei Li; En-Mei Liu; Wen-Kui Xiong; Shuo Wang; Rui Zhu; Yu-Bin Ding; Zhao-Hui Zhong
Journal:  World J Pediatr       Date:  2022-01-11       Impact factor: 2.764

2.  Association of infant antibiotic exposure and risk of childhood asthma: A meta-analysis.

Authors:  Zeyi Zhang; Jingjing Wang; Haixia Wang; Yizhang Li; Yuanmin Jia; Mo Yi; Ou Chen
Journal:  World Allergy Organ J       Date:  2021-12-06       Impact factor: 4.084

3.  Impact of antibiotics on off-target infant gut microbiota and resistance genes in cohort studies.

Authors:  Rebecca M Lebeaux; Juliette C Madan; Quang P Nguyen; Modupe O Coker; Erika F Dade; Yuka Moroishi; Thomas J Palys; Benjamin D Ross; Melinda M Pettigrew; Hilary G Morrison; Margaret R Karagas; Anne G Hoen
Journal:  Pediatr Res       Date:  2022-05-14       Impact factor: 3.953

4.  Long term impact of prophylactic antibiotic use before incision versus after cord clamping on children born by caesarean section: longitudinal study of UK electronic health records.

Authors:  Dana Šumilo; Krishnarajah Nirantharakumar; Brian H Willis; Gavin M Rudge; James Martin; Krishna Gokhale; Rasiah Thayakaran; Nicola J Adderley; Joht Singh Chandan; Kelvin Okoth; Isobel M Harris; Ruth Hewston; Magdalena Skrybant; Jonathan J Deeks; Peter Brocklehurst
Journal:  BMJ       Date:  2022-05-17

Review 5.  Prevention of Asthma: Targets for Intervention.

Authors:  Michelle C Maciag; Wanda Phipatanakul
Journal:  Chest       Date:  2020-04-21       Impact factor: 9.410

6.  Pediatric asthma incidence rates in the United States from 1980 to 2017.

Authors:  Christine C Johnson; Suzanne L Havstad; Dennis R Ownby; Christine L M Joseph; Alexandra R Sitarik; Jocelyn Biagini Myers; Tebeb Gebretsadik; Tina V Hartert; Gurjit K Khurana Hershey; Daniel J Jackson; Robert F Lemanske; Lisa J Martin; Edward M Zoratti; Cynthia M Visness; Patrick H Ryan; Diane R Gold; Fernando D Martinez; Rachel L Miller; Christine M Seroogy; Anne L Wright; James E Gern
Journal:  J Allergy Clin Immunol       Date:  2021-05-06       Impact factor: 10.793

7.  Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome.

Authors:  Tadashi Yamaguchi; Shoji Tsuji; Shohei Akagawa; Yuko Akagawa; Jiro Kino; Sohsaku Yamanouchi; Takahisa Kimata; Masaki Hashiyada; Atsushi Akane; Kazunari Kaneko
Journal:  Nutrients       Date:  2021-01-26       Impact factor: 5.717

8.  A rich meconium metabolome in human infants is associated with early-life gut microbiota composition and reduced allergic sensitization.

Authors:  Charisse Petersen; Darlene L Y Dai; Rozlyn C T Boutin; Hind Sbihi; Malcolm R Sears; Theo J Moraes; Allan B Becker; Meghan B Azad; Piush J Mandhane; Padmaja Subbarao; Stuart E Turvey; B Brett Finlay
Journal:  Cell Rep Med       Date:  2021-04-29

9.  Composition and Associations of the Infant Gut Fungal Microbiota with Environmental Factors and Childhood Allergic Outcomes.

Authors:  Stuart E Turvey; B Brett Finlay; Rozlyn C T Boutin; Hind Sbihi; Ryan J McLaughlin; Aria S Hahn; Kishori M Konwar; Rachelle S Loo; Darlene Dai; Charisse Petersen; Fiona S L Brinkman; Geoffrey L Winsor; Malcolm R Sears; Theo J Moraes; Allan B Becker; Meghan B Azad; Piush J Mandhane; Padmaja Subbarao
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

Review 10.  Microbiota and human allergic diseases: the company we keep.

Authors:  Donata Vercelli
Journal:  Curr Opin Immunol       Date:  2021-06-26       Impact factor: 7.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.